GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » Shiller PE Ratio

BETRF (BetterLife Pharma) Shiller PE Ratio : (As of Jan. 18, 2025)


View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BetterLife Pharma Shiller PE Ratio Historical Data

The historical data trend for BetterLife Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Shiller PE Ratio Chart

BetterLife Pharma Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BetterLife Pharma Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BetterLife Pharma's Shiller PE Ratio

For the Biotechnology subindustry, BetterLife Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BetterLife Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Shiller PE Ratio falls into.



BetterLife Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BetterLife Pharma's E10 for the quarter that ended in Oct. 2024 is calculated as:

For example, BetterLife Pharma's adjusted earnings per share data for the three months ended in Oct. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Oct. 2024 (Change)*Current CPI (Oct. 2024)
=0/127.8378*127.8378
=0.000

Current CPI (Oct. 2024) = 127.8378.

BetterLife Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201501 -0.965 98.209 -1.256
201504 -0.195 99.710 -0.250
201507 -0.303 100.579 -0.385
201510 -0.001 100.500 -0.001
201601 -0.819 100.184 -1.045
201604 -0.392 101.370 -0.494
201607 -0.200 101.844 -0.251
201610 -0.101 102.002 -0.127
201701 -0.083 102.318 -0.104
201704 -0.043 103.029 -0.053
201707 -0.001 103.029 -0.001
201710 0.102 103.424 0.126
201801 -0.032 104.056 -0.039
201804 -0.236 105.320 -0.286
201807 -0.152 106.110 -0.183
201810 -0.308 105.952 -0.372
201901 -0.098 105.557 -0.119
201904 -0.142 107.453 -0.169
201907 -0.214 108.243 -0.253
201910 -0.114 107.927 -0.135
202001 -0.520 108.085 -0.615
202004 0.003 107.216 0.004
202007 -0.067 108.401 -0.079
202010 -0.189 108.638 -0.222
202101 -0.420 109.192 -0.492
202104 -0.032 110.851 -0.037
202107 -0.040 112.431 -0.045
202110 -0.024 113.695 -0.027
202201 -0.040 114.801 -0.045
202204 -0.032 118.357 -0.035
202207 -0.008 120.964 -0.008
202210 -0.037 121.517 -0.039
202301 0.000 121.596 0.000
202304 -0.003 123.571 -0.003
202307 -0.008 124.914 -0.008
202310 0.000 125.310 0.000
202401 -0.007 125.072 -0.007
202404 -0.012 126.890 -0.012
202407 -0.007 128.075 -0.007
202410 0.000 127.838 0.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BetterLife Pharma  (OTCPK:BETRF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BetterLife Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BetterLife Pharma Business Description

Traded in Other Exchanges
Address
1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
Executives
Barbara-jean Anne Bormann-kennedy director, officer: President 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong officer: Chief Financial Officer 2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari director, 10 percent owner 1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian director, officer: Chairman 1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6